[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Mbx Biosciences Inc (MBX)

Mbx Biosciences Inc (MBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,034,080
  • Shares Outstanding, K 48,160
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,970 K
  • EBIT $ -118 M
  • EBITDA $ -118 M
  • 60-Month Beta 0.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.72

Options Overview Details

View History
  • Implied Volatility 76.38% (+4.80%)
  • Historical Volatility 55.89%
  • IV Percentile 2%
  • IV Rank 2.34%
  • IV High 276.76% on 09/16/25
  • IV Low 71.57% on 08/27/26
  • Expected Move (DTE 19) 3.83 (6.07%)
  • Put/Call Vol Ratio 41.50
  • Today's Volume 170
  • Volume Avg (30-Day) 66
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 2,592
  • Open Int (30-Day) 2,683
  • Expected Range 59.18 to 66.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.78
  • Number of Estimates 5
  • High Estimate $-0.69
  • Low Estimate $-0.88
  • Prior Year $-0.63
  • Growth Rate Est. (year over year) -23.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.58 +3.99%
on 07/29/26
72.64 -13.27%
on 08/05/26
+2.94 (+4.90%)
since 07/28/26
3-Month
28.00 +125.00%
on 06/08/26
72.64 -13.27%
on 08/05/26
+31.10 (+97.49%)
since 05/28/26
52-Week
9.63 +554.21%
on 09/12/25
72.64 -13.27%
on 08/05/26
+48.73 (+341.49%)
since 08/28/25

Most Recent Stories

More News
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support...

MBX : 63.00 (-5.11%)
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit

MBX : 63.00 (-5.11%)
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1...

MBX : 63.00 (-5.11%)
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights

One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting

MBX : 63.00 (-5.11%)
MBX's Phase Three Timeline Looks Confident But the Obesity Pivot Remains Undefined

Barchart Research What to Expect from MBX Earnings MBX Generated August 5, 2026 Current Price $67.48 EPS Estimate $$-0.68 Consensus Rating Strong Buy Average Move 6.40% MBX's Phase Three Timeline Looks...

MBX : 63.00 (-5.11%)
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 63.00 (-5.11%)
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company...

MBX : 63.00 (-5.11%)
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration...

MBX : 63.00 (-5.11%)
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium...

MBX : 63.00 (-5.11%)
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 63.00 (-5.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX...

See More

Key Turning Points

3rd Resistance Point 68.25
2nd Resistance Point 67.19
1st Resistance Point 65.10
Last Price 63.00
1st Support Level 61.95
2nd Support Level 60.89
3rd Support Level 58.80

See More

52-Week High 72.64
Last Price 63.00
Fibonacci 61.8% 48.57
Fibonacci 50% 41.13
Fibonacci 38.2% 33.70
52-Week Low 9.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.